[1] Hill NR, Fatoba ST, Oke JL, et al.Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis[J].PLoS One, 2016,11(7):e0158765. DOI: 10.1371/journal.pone.0158765
[2] Bittl JACatheter interventions for hemodialysis fistulas and grafts[J].JACC Cardiovasc Interv, 2010,3(1):1-11. DOI: 10.1016/j.jcin.2009.10.021
[3] Coresh J, Selvin E, Stevens LA, et al.Prevalence of chronic kidney disease in the United States[J].Jama, 2007,298(17):2038-2047. DOI: 10.1001/jama.298.17.2038
[4] KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update[J].Am J Kidney Dis, 2015,66(5):884-930. doi: 10.1053/j.ajkd.2015.07.015.
[5] Beathard GA, Arnold P, Jackson J, et al.Aggressive treatment of early fistula failure[J].Kidney Int, 2003,64(4):1487-1494. doi: 10.1046/j.1523-1755.2003.00210.x.
[6] Caplice NM, Wang S, Tracz M, et al.Neoangiogenesis and the presence of progenitor cells in the venous limb of an arteriovenous fistula in the rat[J].Am J Physiol Renal Physiol, 2007,293(2):F470-475. doi: 10.1152/ajprenal.00067.2007.
[7] Swedberg SH, Brown BG, Sigley R, et al.Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment[J].Circulation, 1989,80(6):1726-1736. doi: 10.1161/01.cir.80.6.1726.
[8] Tigerstedt NM, Savolainen-Peltonen H, Lehti S, et al.Vascular cell kinetics in response to intimal injury ex vivo[J].J Vasc Res, 2010,47(1):35-44. doi: 10.1159/000231719.
[9] Dariushnia SR, Walker TG, Silberzweig JE, et al.Quality Improvement Guidelines for Percutaneous Image-Guided Management of the Thrombosed or Dysfunctional Dialysis Circuit[J].J Vasc Interv Radiol, 2016,27(10):1518-1530. doi: 10.1016/j.jvir.2016.07.015.
[10] Aruny JE, Lewis CA, Cardella JF, et al.Quality improvement guidelines for percutaneous management of the thrombosed or dysfunctional dialysis access. Standards of Practice Committee of the Society of Cardiovascular & Interventional Radiology[J].J Vasc Interv Radiol, 1999,10(4):491-498. doi: 10.1016/s1051-0443(99)70071-0.
[11] Asif A, Lenz O, Merrill D, et al.Percutaneous management of perianastomotic stenosis in arteriovenous fistulae: results of a prospective study[J].Kidney Int, 2006,69(10):1904-1909. doi: 10.1038/sj.ki.5000358.
[12] Pan HB, Liang HL, Lin YH, et al.Metallic stent placement for treating peripheral outflow lesions in native arteriovenous fistula hemodialysis patients after insufficient balloon dilatation[J].AJR Am J Roentgenol, 2005,184(2):403-409. doi: 10.2214/ajr.184.2.01840403.
[13] Vogel PM, Parise CComparison of SMART stent placement for arteriovenous graft salvage versus successful graft PTA[J].J Vasc Interv Radiol, 2005,16(12):1619-1626. doi: 10.1097/01.RVI.0000179792.23867.01.
[14] Maya ID, Allon MOutcomes of thrombosed arteriovenous grafts: comparison of stents vs angioplasty[J].Kidney Int, 2006,69(5):934-937. doi: 10.1038/sj.ki.5000214.
[15] Haskal ZJ, Trerotola S, Dolmatch B, et al.Stent graft versus balloon angioplasty for failing dialysis-access grafts[J].N Engl J Med, 2010,362(6):494-503. DOI: 10.1056/NEJMoa0902045
[16] Aftab SA, Tay KH, Irani FG, et al.Randomized clinical trial of cutting balloon angioplasty versus high-pressure balloon angioplasty in hemodialysis arteriovenous fistula stenoses resistant to conventional balloon angioplasty[J].J Vasc Interv Radiol, 2014,25(2):190-198. DOI: 10.1016/j.jvir.2013.10.020
[17] Unverdorben M, Vallbracht C, Cremers B, et al.Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis[J].Circulation, 2009,119(23):2986-2994. DOI: 10.1161/CIRCULATIONAHA.108.839282
[18] Clever YP, Cremers B, Krauss B, et al.Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells[J].EuroIntervention, 2011,7 Suppl K(K32-42. DOI: 10.4244/EIJV7SKA6
[19] Lai CC, Fang HC, Tseng CJ, et al.Percutaneous angioplasty using a paclitaxel-coated balloon improves target lesion restenosis on inflow lesions of autogenous radiocephalic fistulas: a pilot study[J].J Vasc Interv Radiol, 2014,25(4):535-541. DOI: 10.1016/j.jvir.2013.12.014
[20] Kitrou PM, Katsanos K, Spiliopoulos S, et al.Drug-eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost-effectiveness analysis from a prospective randomized controlled trial (NCT01174472)[J].Eur J Radiol, 2015,84(3):418-423.
[21] Scheller B, Speck U, Schmitt A, et al.Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation[J].J Am Coll Cardiol, 2003,42(8):1415-1420.
[22] Scheller B, Speck U, Abramjuk C, et al.Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis[J].Circulation, 2004,110(7):810-814.
[23] Scheller B, Hehrlein C, Bocksch W, et al.Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J].N Engl J Med, 2006,355(20):2113-2124.
[24] Rittger H, Waliszewski M, Brachmann J, et al.Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter)[J].JACC Cardiovasc Interv, 2015,8(13):1695-1700.
[25] Tepe G, Zeller T, Albrecht T, et al.Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg[J].N Engl J Med, 2008,358(7):689-699.
[26] Dhakam S, Jafferani A, Ahmed H, et al.Safety and efficacy of drug-eluting balloons in the treatment of drug-eluting in-stent restenosis: experience of a tertiary care hospital[J].J Invasive Cardiol, 2012,24(7):335-338.
[27] Ng VG, Mena C, Pietras C, et al.Local delivery of paclitaxel in the treatment of peripheral arterial disease[J].Eur J Clin Invest, 2015,45(3):333-345.
[28] Speck U, Scheller B, Hamm BDrug-coated balloons for restenosis prophylaxis[J].Rofo, 2014,186(4):348-358.
[29] Allon MCurrent management of vascular access[J].Clin J Am Soc Nephrol, 2007,2(4):786-800.
[30] III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000[J].Am J Kidney Dis, 2001,37(1 Suppl 1):S137-181.
[31] Tonnessen BH, Money SREmbracing the fistula first national vascular access improvement initiative[J].J Vasc Surg, 2005,42(3):585-586.
[32] Roy-Chaudhury P, Sukhatme VP, Cheung AKHemodialysis vascular access dysfunction: a cellular and molecular viewpoint[J].J Am Soc Nephrol, 2006,17(4):1112-1127.
[33] Somarathna M, Hwang PT, Millican RC, et al.Nitric oxide releasing nanomatrix gel treatment inhibits venous intimal hyperplasia and improves vascular remodeling in a rodent arteriovenous fistula[J].Biomaterials, 2022,280(121254.
[34] Fransson T, Gotts?ter A, Abdulrasak M, et al.Drug-eluting balloon (DEB) versus plain old balloon angioplasty (POBA) in the treatment of failing dialysis access: A prospective randomized trial[J].J Int Med Res, 2022,50(3):3000605221081662.
[35] Liu C, Wolfers M, Awan BZ, et al.Drug-Coated Balloon Versus Plain Balloon Angioplasty for Hemodialysis Dysfunction: A Meta-Analysis of Randomized Controlled Trials[J].J Am Heart Assoc, 2021,10(23):e022060.
[36] Kocaaslan C, Oztekin A, Bademci MS, et al.A retrospective comparison analysis of results of drug-coated balloon versus plain balloon angioplasty in treatment of juxta-anastomotic de novo stenosis of radiocephalic arteriovenous fistulas[J].J Vasc Access, 2020,21(5):596-601.
